OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
December 13, 2024
Colin McKinlay, the senior director of Chemistry and Delivery Technologies at Nutcracker Therapeutics, discusses current challenges in mRNA and LNP manufacturing as well as innovations that meet these challenges.
The partners will aim to establish a platform that enables rapid development of DPI products.
December 12, 2024
With these agreements, the respective parties will work to advance therapeutic candidates for treating fibrotic diseases, osteoarthritis, and Alzheimer’s disease.
December 10, 2024
Novartis will in-license PTC's PTC518 program, which has the potential become the first oral disease-modifying therapy for Huntington's disease.
December 09, 2024
Centogene NV and ROPAD consortium publish data from a landmark study identifying genetic variants that may respond to innovative cell and gene therapies.
December 08, 2024
Automation technologies provide real potential to improve responsiveness and decision-making in drug development.
December 07, 2024
LNPs have gained solid ground as a drug delivery system for mRNA due to their success in the vaccines arena.
December 06, 2024
Through the agreement, Cambrex will provide accelerated access to clinical development capabilities to Lilly’s biotech collaborators.
December 04, 2024
EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.
With its new offering, Lonza can tailor services to support smart capsule companies with its bi-layer capsule manufacturing technology.